Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool

Journal of Clinical Investigation

Volumn 115, Issue 5, 2005, Pages 1177-1187

  Melchionda, Fraia ^a,b   Fry, Terry J ^a   Milliron, Matthew J ^a   McKirdy, Melissa A ^a   Tagaya, Yutaka ^a   Mackall, Crystal L ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MSC 1928 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HY ANTIGEN; IMMUNOLOGICAL ADJUVANT; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 7;

ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL TIME; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR GROWTH;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; H-Y ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; INTERLEUKIN-15; INTERLEUKIN-7; MICE; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 18244371047     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200523134     Document Type: Article

References (56)

1. Zinkernagel, R.M. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515-546.
2. Berzofsky, J.A., et al. 2004. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 114:450-462. doi:10.1172/ JCI200422674.
3. Gaschen, B., et al. 2002. Diversity considerations in HIV-1 vaccine selection. Science. 296:2354-2360.
4. Wherry, E.J., Blattman, J.N., Murali-Krishna, K., van der Most, R., and Ahmed, R. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77:4911-4927.
5. Dudley, M.E., et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854.
6. Jacob, J., and Baltimore, D. 1999. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature. 399:593-597.
7. Opferman, J.T., Ober, B.T., and Ashton-Rickardt, P.G. 1999. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science. 283:1745-1748.
8. + T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nat. Immunol. 2:415-422.
9. Gett, A.V., Sallusto, F., Lanzavecchia, A., and Geginat, J. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4:355-360.
10. Hou, S., Hyland, L., Ryan, K.W., Portner, A., and Doherty, P.C. 1994. Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature. 369:652-654.
11. Iezzi, G., Karjalamen, K., and Lanzavecchia, A. 1998. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 8:89-95.
12. Schluns, K.S., Kieper, W.C., Jameson, S.C., and Lefrancois, L. 2000. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1:426-432.
13. Tan, J.T., et al. 2001. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. U. S. A. 98:8732-8737.
14. Fry, T.J., et al. 2003. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood. 101:2294-2299.
15. van Stipdonk, M.J., Lemmens, E.E., and Schoenberger, S.P. 2001. Naive CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiacion. Nat Immunol. 2:423-429.
16. Kaech, S.M., et al. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4:1191-1198.
17. Boise, L.H., Minn, A.J., June, C.H., Lindsten, T., and Thompson, C.B. 1995. Growth factors can enhance lymphocyte survival without committing the cell to undergo cell division. Proc. Natl. Acad. Sci. U. S. A. 92:5491-5495.
18. Zhang, X., Sun, S., Hwang, I., Tough, D.F., and Sprent, J. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 8:591-599.
19. Ku, C.C., Murakami, M., Sakamoto, A., Kappler, J., and Marrack, P. 2000. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 288:675-678.
20. Tan, J.T., et al. 2002. Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 195:1523-1532.
21. Kieper, W.C., et al. 2002. Overexpression of interleukin (IL)-7 leads to IL-15-independent generation of memory phenotype CD8+ T cells. J. Exp. Med. 195:1533-1539.
22. Sin, J.I., Kim, J., Pachuk, C., Weiner, D.B., and Patchuk, C. 2000. Interleukin 7 can enhance antigen-specific cytotoxic-T-lymphocyte and/or Th2-type immune responses in vivo. Clin. Diagn. Lab. Immunol. 7:751-758.
23. Cayeux, S., Beck, C., Aicher, A., Dorken, B., and Blankenstein, T. 1995. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur. J. Immunol 25:2325-2331.
24. Kim, J.H., et al. 1994. Consequences of stable transduction and antigen-inducible expression of the human interleukin-7 gene on tetanus-toxoid-specific T cells. Hum. Gene Ther. 5:1457-1466.
25. Maeurer, M.J., et al. 2000. Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice. Infect. Immun. 68:2962-2970.
26. Blattman, J.N., et al. 2003. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 9:540-547.
27. Rubinstein, M.P., et al. 2002. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J. Immunol. 169:4928-4935.
28. Oh, S., Berzofsky, J.A., Butke, D.S., Waldmann, T.A., and Perera, L.P. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. U. S. A. 100:3392-3397.
29. Khan, I.A., and Casciotti, L. 1999. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J. Immunol. 163:4503-4509.
30. Xin, K.Q., et al. 1999. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine. 17:858-866.
31. Bolotin, E., Annett, G., Parkman, R., and Weinberg, K. 1999. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 23:783-788.
32. Fry, T.J., et al. 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood. 97:2983-2990.
33. Napolitano, L.A., et al. 2001. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 7:73-79.
34. Marks-Konczalik, J., et al. 2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97:11445-11450.
35. Roper, M., et al. 1992. A phase I study of interleukin-2 in children with cancer. Am. J. Pediatr. Hematol. Oncol. 14:305-311.
36. Kammula, U.S., White, D.E., and Rosenberg, S.A. 1998. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 83:797-805.
37. Geiselhart, L.A., et al. 2001. IL-7 administration alters the CD4:CD8 ratio, increases T cell numbers, and increases T cell function in the absence of activation. J. Immunol. 166:3019-3027.
38. Storek, J., et al. 2003. Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation monkeys. Blood. 101:4209-4218.
39. Dubois, S., Mariner, J., Waldmann, T.A., and Tagaya, Y. 2002. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 17:537-547.
40. Soares, M.V., et al. 1998. IL-7-dependenc extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J. Immunol. 161:5909-5917.
41. Mackall, C.L., et al. 1996. Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 156:4609-4616.
42. Goldrath, A.W., and Sevan, M.J. 1999 Aug. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 11:183-190.
43. Ernst, B., Lee, D.S., Chang, J.M., Sprent, J., and Surh, C.D. 1999. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 11:173-181.
44. Berard, M., Brandt, K., Bulfone-Paus, S., and Tough, D.F. 2003. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 170:5018-5026.
45. Melchionda, F., McKirdy, M.K., Medeiros, F., Fry, T.J., and Mackall, C.L. 2004. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J. Immunother. 27:329-338.
46. Rosenberg, S.A., Yang, J.C., and Restifo, N.P. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-915.
47. Cerundolo,, V., Hermans, I.F., and Salio, M. 2004. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5:7-10.
48. Kaech, S.M., Wherry, E.J., and Ahmed; R. 2002. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2:251-262.
49. Yajima, T., et al. 2002. Overexpression of IL-15 in vivo increases antigen-driven memory CD8+ T cells following a microbe exposure. J. Immunol. 168:1198-1203.
50. Yewdell, J.W., and Del Val, M. 2004. Immunodominance in TCD8+ responses to viruses: cell biology, cellular immunology, and mathematical models. Immunity. 21:149-153.
51. Melchionda, F., McKirdy, M.K., Medeiros, F., Fry, T.J., and Mackall, C.L. 2004. Escape from immune surveillance does not result in tolerance to tumor-associated antigens. J. Immunother. 27:329-338.
52. Sinha, M.L., Fry, T.J., Fowler, D.H., Miller, G., and Mackall, C.L. 2002. Interleukin 7 worsens graft-versus-host disease. Blood. 100:2642-2649.
53. Eden, P.A., et al. 1999. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus. J. Immunol. 162:4502-4510.
54. De Boer, R.J., Homann, D., and Perelson, A.S. 2003. Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J. Immunol. 171:3928-3935.
55. NIH. 2005. Interleukin-7 in treating patients with refractory solid tumors. http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid= 304451&version=patient&protocolsearchid=1508293.
56. Fry, T.J., Christensen, B.L., Komschlies, K.L., Gress, R.E., and Mackall, C.L. 2001. Interleukin-7 restores immunity in athymic T cell-depleted hosts. Blood. 997:1525-1533.